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Abstract 
The design, synthesis and biological evaluation of eighteen ferrocenyl derivatives (4A-12A and 4B-
12B) of the most-well known drug against schistosomiasis, namely praziquantel (PZQ), are reported. 
These compounds which have been all isolated as racemates were unambiguously characterized by 
1
H 
and 
13
C NMR spectroscopy, mass spectrometry and elemental analysis as well as by X-ray 
crystallography for 4A, 5A and 7A. Cytotoxicity studies revealed that the complexes were moderately 
toxic towards a cervical cancer cell line (HeLa) and, importantly, significantly less active towards a 
noncancerous cell line (MRC-5). The in vitro anthelmintic activity of the eighteen ferrocenyl PZQ 
derivatives was tested against Schistosoma mansoni and values in the micromolar range (26-68 µM) 
were determined for the four most active compounds. It was also demonstrated using two compounds of 
the series as models (8A and 8B) that the complexes were stable when incubated for 24 h at 37°C in 
human plasma. 
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Introduction. 
Schistosomiasis is a parasitic disease caused by trematodes of the genus Schistosoma. It is a major 
health problem worldwide, particularly in tropical regions where 280,000 deaths are reported annually.
1, 
2
 In addition, more than 207 million people, mostly in Africa, are infected and nearly 800 million are at 
risk of being infected.
3
 Currently, praziquantel (PZQ, Figure 1) is widely used, as a racemic mixture, to 
control this infection in human as well as in animals. PZQ exhibits a broad spectrum anthelmintic 
activity against all five human Schistosoma species. Although no clear evidence exist to date, the 
voltage-gated Ca
2+
 channels in the membrane are believed to be one of the possible targets for PZQ.
4, 5
 
Despite its success, PZQ suffers from several drawbacks. For example, its metabolic stability is rather 
low. PZQ is indeed rapidly converted in vivo into the less active or inactive PZQ-OH (Figure 1) by 
hydroxylation of the cyclohexane ring.
6, 7
 Furthermore, PZQ is inactive against juvenile schistosomes, 
hence it is necessary to retreat patients after a few weeks to remove those parasites that have since 
matured.
5
 But potentially more worryingly, as millions of people are regularly treated with this drug, it 
is likely PZQ resistant parasites emerge in the near future.
4, 5
 Indeed, reduced susceptibility of 
Schistosoma mansoni to PZQ was already observed.
5, 8
  
In order to overcome these drawbacks, chemical modifications on the PZQ structure were 
undertaken. For example, Todd et al. reported several PZQ derivatives with a modification at the C10 
position of the aromatic ring (see Figure 1 for the atom numbering in the PZQ structure).
9
 They 
concluded that the aromatic part is not a suitable position for structural modification. Robert, Meunier et 
al. disclosed the synthesis and biological evaluation of trioxaquantels which are hybrid molecules made 
of the 1,2,4-trioxane unit of the antimalarial drug artemisin and the pyrazinoisoquinoline moiety of 
PZQ.
10
 Only one of their compounds was found have a moderate anti-parasitic activity. Recently, 
Domling et al. reported the synthesis of PZQ derivatives using a Ugi 4-component reaction
11
 and they 
observed that a few of their analogues were as active as the parent drug PZQ. Of high interest, 
Vennerstrom and co-workers recently prepared PZQ derivatives with activity against the juvenile stage 
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of S. mansoni.
12
 Nonetheless, to the best of our knowledge, no lead compound suitable for further pre-
clinical testing was identified in these studies. This fact clearly emphasizes the need for a fundamentally 
different approach for the discovery of novel PZQ derivatives active against schistosomiasis. 
With this in mind, we envisaged to derivatize PZQ with organometallic moieties as previously 
undertaken with anticancer, antibacterial and antimalarial drugs.
13-26
 This strategy was found very 
successful with ferroquine (FQ), a ferrocenyl analogue of the antimalarial drug chloroquine (CQ), as FQ 
is active on CQ-resistant Plasmodium falciparum strains. Furthermore, intensive chemical biology 
studies have recently allowed unveiling additional modes of action for FQ compared to the parent drug 
in FQ, which were attributed to the presence of the organometallic unit.
19, 27
 It is anticipated that these 
additional modes of action will help prolonging the period of resistance development. Of note, Sánchez-
Delgado and co-workers reported the preparation of ruthenium half-sandwich analogues of CQ which 
were found to be highly potent and to overcome the CQ resistance.
28
 Organometallic compounds have 
also been investigated for their activity against other parasites such as the trypanosome Trypanosoma 
cruzi (T. cruzi) or Echinococcus multilocularis metacestodes.
29-31
 For example, a ruthenium half-
sandwich complex of the antifungal drug clotrimazole was found to be 58 times more potent than the 
parent drug in vitro against T. cruzi.
29
  
Due to these promising results obtained with other parasitic drugs, we have embarked on a project to 
evaluate the potential of ferrocenyl derivatives of PZQ against Schistosoma mansoni. In analogy to what 
observed for FQ, we postulated that the derivatization of PZQ with a ferrocenyl moiety could potentially 
prevent future resistance as well as render the compound active against the juvenile stage of the parasite 
which is refractory to PZQ. In this article, we report our initial results on the synthesis and biological 
activity of the first organometallic derivatives of PZQ. As shown in Figure 1, our concept was to replace 
the cyclohexane ring of PZQ with a ferrocenyl unit as it has been reported that the replacement of the 
cyclohexane ring of PZQ by a benzene ring was not significantly altering the activity.
9, 11
 
32
 Moreover, 
we anticipated that the in vivo transformation of PZQ into PZQ-OH could be avoided due to the missing 
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cyclohexane ring in our derivatives. In this study, two different structural classes (Type-A and –B, 
Figure 1) of ferrocenyl-praziquantel (Fc-PZQ) derivatives were investigated. Ferrocenyl derivatives in 
Type-A analogues are directly attached to the praziquanmine (1, Scheme 1) residue with different 
linkers. In contrast, Type-B analogues are structurally closer to PZQ as the ferrocenyl moieties are 
linked to a piperidine unit replacing the cyclohexane ring attached to the praziquanamine via an amide 
bond (Figure 1).  
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Figure 1. Structures including atom numbering of PZQ and of its major metabolite PZQ-OH as well as 
of the Fc-PZQ derivatives (Type-A and -B) studied in this report.  
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Results and Discussion. 
Synthesis. The syntheses of the Fc-PZQ analogues are schematically presented in Scheme 1. For 
more details on the structure of the compounds, the readers are referred to Table 1. It should be also 
noted that all chiral compounds described in this study are racemates. Specifically, praziquanamine (1) 
was prepared following a previously reported literature procedure.
10
 1 was then converted into 3 by 
treatment with 1-Boc-4-piperidinedicarboxylic acid and followed by the Boc group deprotection with 
TFA. All ferrocene-containing carboxylic acid derivatives
33-35
 and 
trimethyl(ferrocenylmethyl)ammonium iodide
36
 are either commercially available or were prepared 
following standard literature procedures. The ferrocene-containing carboxylic acids were then attached 
to either 1 or 3 via a HATU mediated amide coupling reaction to provide 4A, 6A-12A and 4B, 6B-12B, 
respectively. 5A and 5B were prepared by treatment of 1 and 3, respectively, with 
trimethyl(ferrocenylmethyl)ammonium iodide and K2CO3 in acetonitrile using a synthetic method 
similar to what employed by Spiccia et al.
37
 All new compounds were unambiguously characterized 
using 
1
H and 
13
C NMR spectroscopy, ESI mass spectrometry and elemental analysis (see experimental 
section and SI). The presence of rotamers in solution for all Fc-PZQ derivatives except for 4A, 5A and 
12A was ascertained by analysis of their 
1
H and 
13
C NMR spectra. In ESI-mass spectrometry (positive 
detection mode), most of the compounds were identified as their [M+Na]
+
 species or, in a few 
exceptions, as their [M+H]
+
 or [M+K]
+
 species. Of note, all ferrocenyl compounds were found to be 
soluble in aqueous solutions containing 0.5% of DMSO up to 100 M concentration. 
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Scheme 1. Synthesis of Fc-PZQ derivatives. 
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Table 1. Structures and yields of Fc-PZQ derivatives   
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X-ray Crystallography. The molecular structures of 4A, 5A, 7A were confirmed by the 
determination of their respective X-ray single crystal structures. All the compounds crystallized as their 
racemates. ORTEP plots are presented in Figures 2, S1 and S2, respectively. Table S1 (in the SI) 
contains the relevant crystallographic data and parameters. For the three Fc-PZQ derivatives, the 
interatomic distances and angles are typical for such compounds.
38
 For example, the average distances 
between the carbon atoms of the Cp rings of ferrocene and the iron ion fluctuate between 2.026 – 2.059 
Ǻ for 4A. 
 
 
Figure 2. The molecular structure of 4A (one enantiomer is shown), showing the numbering scheme 
and the displacement ellipsoids drawn at the 50% probability level. Hydrogen atoms are omitted for 
clarity. 
Biological Evaluation. An ideal antiparasitic agent is supposed to kill selectively the parasites 
without, or to a significantly less extend, being harmful to the host. We therefore evaluated the toxic 
behavior of our Fc-PZQ derivatives towards two mammalian cell lines, namely a cervical cancer cell 
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line (HeLa) and a non-cancerous cell line (MRC-5). Cisplatin, a platinum based anticancer drug, was 
used as a reference compound. The resulting IC50 values are summarized in Table 2. In general, the 
ferrocenyl compounds studied in this work were found to be moderately cytotoxic towards HeLa cells. 
Interestingly, a significant decrease in cytotoxicity was observed for all compounds except 11B when 
their activity was analyzed on a non-transformed cell line. This shows an interesting selectivity towards 
cancer cells. Among all the compounds tested, 9A, which has the longer CH2-linker between the 
praziquanamine and the ferrocenyl moiety, inhibited HeLa cell viability with a half inhibitory 
concentration (IC50) of 16.9 ± 1.0 μM, thus appearing to be the most cytotoxic compound of this study. 
The IC50 value displayed by 9A was comparable to that of cisplatin (IC50= 11.5 ± 2.9 μM). Interestingly, 
9A was much more selective towards the cancer cell line studied in this work compared to cisplatin. 
Similar results were obtained for 9B. Shortening the length of the linker between the organic and the 
ferrocenyl moiety resulted in reduced anticancer activity (9>8>7>6, Table 2), a behavior that could be 
attributed to a decrease in lipophilicity. Such a trend was further confirmed with 12A, which was more 
cytotoxic than 4A despite the presence of a similar linker. However, the presence of two 
praziquanamine moieties attached to the ferrocenyl core in 12A makes the compound certainly more 
lipophilic compared to 4A.  
We then tested the Fc-PZQ derivatives (4A/B-12A/B) against adult S. mansoni to assess their 
anthelmintic potential. PZQ was used as a reference compound and the results obtained are listed in 
Table 2. Fourteen compounds did not show activity at the highest concentration tested (30 µg/ml). Four 
compounds (5A, 7-9A), which displayed activity at 30 µg/ml, were further studied and IC50 of 25.6-68 
µM calculated. The highest activity was observed with 8A, which displayed an IC50 of 25.6 µM. All 
compounds were considerably less active than PZQ (0.1 µM). 
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Table 2. Anthelmintic activity against Schistosoma mansoni and cytotoxicity against HeLa and MRC-
5 cells of Fc-PZQ derivatives. 
Compounds 
Activity against 
Schistosoma mansoni (μM) 
 
IC50 values for two different cell lines (μM) 
HeLa MRC-5 
A B A B A B 
4 >72* >70* > 100 > 100 > 100 > 100 
5 68 >59* 57.9 ± 6.4 81.0 ± 0.2 >100 93.9 ± 2.1 
6 >35* >56* 81.1 ± 2.2 78.0 ± 0.9 > 100 > 100 
7 51.6 >54* 50.6 ± 4.8 ND > 100 ND 
8 25.6 >53* 24.2 ± 3.5 28.9 ± 0.8 62.3 ± 1.3 70.6 ± 2.8 
9 48.6 >52* 16.9 ± 1.0 18.9 ± 1.5 37.0 ± 1.9 36.1 ± 2.1 
10 >42* >37* > 100 ND > 100 ND 
11 >43* >37* 97.0 ± 4.2 > 100 > 100 42.4± 3.2 
12 >47* >35* 26.9 ± 1.6 ND 64.7 ± 5.4 ND 
PZQ 0.1 > 100 ND 
Cisplatin ND 11.5 ± 2.9 7.9 ± 1.2 
ND = Not determined  
     *    = Compound did not show antischistosomal activity at the highest concentration tested (30 µg/ml) 
 
 
Stability in human plasma. In order to obtain preliminary insights into the behaviour of our Fc-PZQ 
derivatives under physiological conditions, the stability of the most active compound 8A and of its B-
type analogue (8B) in human plasma was assessed. Specifically, 8A and 8B were incubated in human 
plasma for 24 h at 37°C and their stability was checked using a LC-MS technique (see experimental 
section for details).
39
 The results were compared with that obtained for the parent drug PZQ in the same 
assay. As shown in Figures S3, S4, S5 in SI, similarly to PZQ, no significant changes was observed 
either in the UV traces or in the ratio of diazepam (internal standard) and 8A or 8B (see table S2 in SI) 
even after 24 h; suggesting that our Fc-PZQ derivatives are stable under physiological conditions.  
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Conclusion.  
There is undoubtedly an urgent need for the discovery of novel drugs against schistosomiasis. 
Currently, this parasitic disease which affects millions of people worldwide is successfully treated with 
a single drug, namely PZQ. However, as the at risk population is regularly being treated with PZQ, there 
are indications that this wide scale use could lead in the emergence of PZQ resistant parasites in the near 
future. In this work, we have envisaged an alternative method to enlarge the chemical space of potential 
drug candidates. Hence, we have successfully derivatized PZQ with different ferrocenyl moieties to give 
eighteen new Fc-PZQ derivatives that were unambiguously characterized including by X-ray 
crystallography for three compounds. It was demonstrated using two compounds of the series as models 
(8A and 8B) that the complexes were stable when incubated for 24 h at 37°C in human plasma. 
Cytotoxic studies on cancerous (HeLa) and non-cancerous (MRC-5) cell lines showed that the Fc-PZQs 
were significantly less active towards the healthy cell line than the cancer cell line studied in this work, 
except for one compound. An increase in the cytotoxicity against HeLa cells was correlated with an 
increase in the length of the linker between the organic and the ferrocenyl moieties, and this for both 
Type-A and -B compounds. The Fc-PZQ compounds were found to have an anthelmintic activity in the 
micromolar range when tested against S. mansoni in vitro. Although the activity of the best compound is 
not sufficient to proceed into further in vivo testing, this study opens new avenues in the search for 
novel drug candidates against schistosomiasis. Further work with different types of organometallic 
compounds has been initiated in our laboratories and our results will be published in due course. 
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Experimental section. 
Materials. All chemicals were of reagent grade quality or better, obtained from commercial suppliers 
and used without further purification. Solvents were used as received or dried over molecular sieves. All 
preparations were carried out using standard Schlenk techniques. Praziquanamine (1), 3-
ferrocenylpropanoic acid, 4-ferrocenylbutyric acid, 5-ferrocenylpentanoic acid, 4,4-
diferrocenoylbutanoic acid, 4,4-diferrocenoylpentanoic acid and trimethyl(ferrocenylmethyl)ammonium 
iodide were prepared following standard literature procedures.
10,33-36
 All new compounds whose 
biological activity was evaluated in this work have a purity ≥95% as confirmed by elemental 
microanalyses. 
Instrumentation and Methods.
 1
H and
 13
C NMR spectra were recorded in deuterated solvents on 400 
(
1
H: 400 MHz, 
13
C: 100.6 MHz) or 500 (
1
H: 500 MHz, 
13
C: 126 MHz) MHz spectrometers at room 
temperature. The chemical shifts, δ, are reported in ppm (parts per million). The residual solvent peaks 
have been used as an internal reference. The abbreviations for the peak multiplicities are as follows: s 
(singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet), and br (broad). The 
1
H and 
13
C signals were assigned with the help of 2D NMR techniques and by comparison with 
previously reported NMR spectra of other PZQ derivatives.
11, 40
 
1
H and 
13
C signal assignments follow 
the atom numbering presented in Figure 1. ESI mass spectra were recorded on a Bruker Esquire 6000 
spectrometer. Elemental microanalyses were performed on a LecoCHNS-932 elemental analyser.  
X-ray Crystallography. Crystallographic data were collected at 183(2) K on an Oxford Diffraction 
Xcalibur system with a Ruby detector using Mo Kα radiation (λ = 0.7107 Å) that was graphite-
monochromated. Suitable crystals were covered with oil (Infineum V8512, formerly known as Paratone 
N), placed on a nylon loop that is mounted in a CrystalCap Magnetic™ from Hampton Research and 
immediately transferred to the diffractometer. The program suite CrysAlis
Pro
 was used for data 
collection, multi-scan absorption correction and data reduction.
41
 The structures were solved with direct 
methods using SIR97
42
 and were refined by full-matrix least-squares methods on F
2
 with SHELXL-
 14 
97.
43
 The structure of 7A contains 2 molecules in the asymmetric unit, it is racemically twinned and one 
of the ferrocene rings had to be refined with the help of DELU restraints. The structures were checked 
for higher symmetry with help of the program Platon.
44
 CCDC 892689 – 892691 contain the 
supplementary crystallographic data for this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Stability of 8A, 8B and PZQ in human plasma.
39
 The human plasma was provided by 
the Blutspendezentrum, Zurich, Switzerland. Stock solutions in DMSO of 1.6 mM of 8A, 8B and PZQ 
and of 800 μM of diazepam (internal standard, obtained from Sigma-Aldrich) were first prepared. 12.5 
μL of the solution containing the compound to be studied and 12.5 μL of the diazepam solution were 
added to 975 μL of plasma. The resulting solution was shaken gently (ca. 300 rpm) at 37°C for 24 h. 
Afterwards, 6 mL of a 2/1 (v/v) methyl-tert-butyl ether/CH2Cl2 mixture was added to the plasma 
solution and the mixture was shaken for 15 min at room temperature and finally centrifuged at 2000x g 
at 4 °C for 10 min. Finally, the organic layer was separated from the water phase and the solvent was 
evaporated with the help of a nitrogen flow. The resulting residue was dissolved in 130 μL of a 8/5 (v/v) 
CH3CN/H2O mixture containing 0.02% TFA and 0.05% HCOOH. 40 μL of this mixture was then 
injected into the HPLC (Acquity Ultra Performance LC, Waters) that was connected to a mass 
spectrometer (Bruker Esquire 6000) operated in ESI mode. The reverse phase column used was a 
Nucleosil 100-5 C18 column (250 × 3 mm) with a flow rate of 0.5 mL min
-1
 and UV-absorption was 
measured at 220 nm. The runs were performed with a linear gradient of A (acetonitrile (Sigma-Aldrich 
HPLC-grade) and B (distilled water containing 0.02% TFA and 0.05% HCOOH): t = 0-3 min, 40% A; 
t = 60 min, 50% A; t = 16 min, 90% A; t = 20 min, 100% A; t = 23 min, 100% A; t = 25 min, 40% A. 
Cell Culture. Human cervical carcinoma cells (HeLa) cells were cultured in DMEM (Gibco) 
supplemented with 5% fetal calf serum (FCS, Gibco), 100 U/ml penicillin, 100 g/ml streptomycin at 
37°C and 5% CO2. The normal human fetal lung fibroblast MRC-5 cell line was maintained in F-10 
medium (Gibco) supplemented with 10% FCS (Gibco), penicillin (100 U/ml), and streptomycin (100 
 15 
g/ml). 
Cytotoxicity Studies. Cytotoxicity studies were performed on two different cell lines, namely HeLa, 
and MRC-5, by a fluorometric cell viability assay using Resazurin (Promocell GmbH). Briefly, one day 
before treatment, cells were seeded in triplicates in 96-well plates at a density of 4 x 10
3
 cells/well for 
HeLa and 7 x 10
3
 for MRC-5 in 100l growth medium. Upon treating cells with increasing 
concentrations of Fc-PZQ derivatives for 48h, the medium was removed, and 100l complete medium 
containing Resazurin (0.2 mg/ml final concentration) were added. After 4h of incubation at 37
o
C, 
fluorescence of the highly red fluorescent product Resorufin was quantified at 590 nm emission with 
540 nm excitation wavelength in a SpectraMax M5 microplate Reader. 
Determination of antiparasitic acitivity against Schistosoma mansoni. Studies were approved by 
the local veterinary agency (permit 2070). Female NMRI mice (n=5, obtained from Harlan Laboratories 
(Horst, the Netherlands)), were subcutaneously infected with ~ 100 cercarciae following standard 
procedures.
45
 Seven weeks post-infection adult S. mansoni were removed from the hepatic portal system 
and mesenteric veins  and cultured in RPMI 1640 culture medium (supplemented with 5% inactivated 
foetal calf serum (iFCS) and 100 U/mL penicillin and 100 µg/mL streptomycin (Invitrogen, Carlsbad, 
USA)) at 37 °C in an atmosphere of 5% CO2 until usage.  
For the determination of activity against adult flukes all drugs were initially tested at a concentration 
of 30 µg/ml, using DMSO stock solutions (conc. 10 mg/ml) diluted in supplemented RPMI1640 
medium within 24 flat bottom well plates (BD Falcon, USA) with a final volume of 2 ml per well. Three 
worms of both sexes were placed into each well. Wells with the highest concentration of DMSO in 
medium served as controls. PZQ served as positive control, concentrations of 0.11, 0.33, 1.1 and 3.3 
µg/ml were used to determine the IC50 value. Phenotypes were monitored after 72 h using the motility 
scale described by Ramirez et al.
46
 and an inverse microscope (Carl Zeiss, Germany, magnification 
80x). Compounds presenting antischistosomal activity were characterized further. Therefore three 
additional concentrations of selected test drugs were tested (1.1, 3.3 and 10 µg/ml) as described above. 
 16 
Each experiment was performed at least three times. IC50 values of active compounds were calculated 
with CompuSyn software (Version 3.0.1, 2007; ComboSyn, Inc) as described before.
47
 
  
Synthesis. 
General procedure for amide coupling (GP-1). To a stirred solution of the carboxylic acid in DMF, 
HATU and DIPEA were successively added and the mixture was allowed to stir for 30 min under a 
nitrogen atmosphere. The appropriate amine dissolved in DMF is then added and the mixture stirred at 
room temperature. The reaction mixture was then diluted with EtOAc and washed with 0.5 M HCl, H2O 
and brine. The organic phase was then dried over anhydrous Na2SO4, filtered and concentrated. 
Compounds were purified either by washing with diethyl ether or by flash column chromatography on 
silica gel. 
Compound 4A. 4A was synthesized following GP-1. Ferrocene carboxylic acid (113 mg, 0.49 
mmol), praziquanamine (100 mg, 0.49 mmol), HATU (279 mg, 0.73 mmol), DIPEA (128 mg, 0.99 
mmol), DMF (3 mL) and reaction time (20 h). Flash column chromatography (silica gel, hexane:EtOAc 
2:1→0:1) gave 4A as an orange solid (yield: 127 mg, 62%). Rf = 0.68 (silica gel, EtOAc).
 1
H NMR (500 
MHz, CDCl3): δ (ppm) 2.65-2.71 (m, 1H, H7), 2.77-2.82 (m, 1H, H6), 2.88-2.93 (m, 2H, H1 and H7), 
4.01 (d, 1H, H3), 4.16 (s, 5H, C5H5), 4.30-4.32 (m, 2H, C5H4), 4.55 (s, br, 1H, C5H4), 4.59 (s, br, 1H, 
C5H4), 4.73-4.76 (m, 1H, H6), 4.84-4.86 (m, 1H, H11b), 4.93 (d, 1H, H3), 5.02 (m, 1H, H1), 7.12-7.28 
(m, 4H, C6H4). 
13
C{
1
H} NMR (126 MHz, CDCl3): δ (ppm) 28.7 (C7), 38.8 (C6), 47.2 (C1), 50.6 (C3), 
54.7 (C11), 69.3 (C5H4), 69.8 (C5H4), 70.0 (C5H5), 70.3 (C5H4), 71.7 (C5H4), 76.2 (C5H4), 125.4 (C6H4), 
126.9 (C6H4), 127.5 (C6H4), 129.4 (C6H4), 132.7 (C6H4), 134.9 (C6H4), 164.8 (C4), 170.2 (N-CO-C5H4). 
ESI-MS (pos. detection mode): m/z (%): 437.1 (80) [M+Na]
+
, 851.1 (100) [2M+Na]
+
. Anal. calcd. for 
C23H22FeN2O2: C 66.68, H 5.35, N 6.76. Found: C 66.92, H 5.17, N 6.66. 
Compound 5A. A mixture of trimethyl(ferrocenylmethyl)ammonium iodide (285 mg, 0.74 mmol), 
praziquanamine (100 mg, 0.49 mmol) and K2CO3 (126 mg, 0.91 mmol) in CH3CN (20 mL) was 
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refluxed under N2 atmosphere. After 16 h, the reaction mixture was cooled to room temperature and 
K2CO3 was removed by filtration. The solvent was removed and the resulting residue was subjected to 
flash column chromatography (silica gel, EtOAc:MeOH 15:1→10:1) to give 5A as a yellow solid 
(yield: 115 mg, 58%). Rf = 0.40 (silica gel, EtOAc). 
1
H NMR (401 MHz, CDCl3): δ (ppm) 2.27-2.33 (m, 
1H, H1), 2.72 (m, 1H, H7), 2.82-2.96 (m, 3H, H7, H6, H3), 3.51-3.55 (m, 4H, C5H4-CH2, H1, H3), 
4.16-4.22 (m, 9H, C5H5 and C5H4), 4.77-4.83 (m, 2H, H6, H11b), 7.10-7.29 (m, 4H, C6H4). 
13
C{
1
H} 
NMR (100.6 MHz, CDCl3): δ (ppm) 28.7 (C7), 38.6 (C6), 55.4 (C11b), 55.5 (C1), 56.4 (C3), 57 (C5H4-
CH2), 68.5 (C5H4), 68.6 (C5H5), 70.0 (C5H4), 70.3 (C5H4), 81.1 (C5H4), 124.6 (C6H4), 126.5 (C6H4), 
126.9 (C6H4), 129.2 (C6H4), 134.4 (C6H4), 134.9 (C6H4), 166.4 (C4). ESI-MS (pos. detection mode): m/z 
(%): 423.1 (70) [M+Na]
+
, 439.0 (40) [M+K]
+
 823.2 (100) [2M+Na]
+
. Anal. calcd. for C23H24FeN2O: C 
69.01, H 6.04, N 7.00. Found: C 69.21, H 6.11, N 6.95. 
Compound 6A. 6A was synthesized following GP-1. Ferrocenyl acetic acid (200 mg, 0.82 mmol), 
praziquanamine (234 mg, 1.16 mmol), HATU (440 mg, 1.16 mmol), DIPEA (199 mg, 1.54 mmol), 4 
mL DMF and 7 h reaction time. Flash column chromatography (filter column on alumina, 
hexane:EtOAc 4:1→0:1) gave a brown solid. The solid was dissolved in 1:1 hexane:EtOAc mixture and 
kept at -20 °C for one week. The resulting precipitate was collected by filtration and washed with Et2O 
to give 6A (yield: 128 mg, 36%). Note: the compound was found to be unstable on silica and slowly 
decomposes on alumina. 
1
H NMR (400 MHz, CDCl3): δ (ppm) 2.74-3.10 (m, 4H, H1, H6, 2×H7), 3.5 
(s, 2H, C5H4-CH2-CO), 3.61-3.72 (min) and 4.08-4.50 (maj) (rotamers, m, 11H, H3, C5H5 and C5H4), 
4.61 (min) and 4.82-4.85 (maj) (rotamers, m, 2H, H6, H11b), 5.09 (m, 1H, H1), 7.10-7.29 (m, 4H, 
C6H4). 
13
C{
1
H} NMR (100.6 MHz, CDCl3): δ (ppm) 28.7 (maj) and 28.8 (min) (rotamers, C7), 35.1 
(maj) and 35.5 (min) (rotamers, C5H4-CH2-CO-N), 38.6 (min) and 39.1 (maj) (rotamers, C6), 45.2 (maj) 
and 46.2 (min) (rotamers, C1), 49.5 (maj) and 49.9 (min) (rotamers, C3), 54.8 (maj) and 55.3 (min) 
(rotamers, C11b), 67.8 (min) and 68.0 (maj) (rotamers, C5H4), 68.1 (maj) and 68.3 (min) (rotamers, 
C5H4), 68.8 (min) and 68.9 (maj) (rotamers, C5H5), 69.2 (C5H4), 80.7 (maj) and 81.3 (min) (rotamers, 
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C5H4), 125.2 (min) and 125.5 (maj) (rotamers, C6H4), 126.9 (min) and 127.0 (maj) (rotamers, C6H4), 
127.5 (maj) and 127.6 (min) (rotamers, C6H4), 129.3 (maj) and 129.6 (min) (rotamers, C6H4), 132.2 
(min) and 132.6 (maj) (rotamers, C6H4), 134.7 (maj) and 135.4 (min) (rotamers, C6H4), 164.1 (maj) and 
165.1 (min) (rotamers, C4), 169.2 (min) and 169.6 (maj) (rotamers, C5H4-CH2-CO-N). ESI-MS (pos. 
detection mode): m/z (%): 451.1 (100) [M+Na]
+
. Anal. calcd. for C24H24FeN2O2: C 67.30, H 5.65, N 
6.54. Found: C 67.02, H 5.49, N 6.61. 
Compound 7A. 7A was synthesized following GP-1. 3-Ferrocenylpropanoic acid (126 mg, 0.49 
mmol), praziquanamine (99 mg, 0.49 mmol), HATU (279 mg, 0.74 mmol), DIPEA (126 mg, 0.98 
mmol), 4 mL DMF and 7 h reaction time. Flash column chromatography (silica gel, hexane:EtOAc 
1:2→0:1) gave 7A as an orange sticky solid (yield: 141 mg, 65%). Rf = 0.19 (silica gel, hexane:EtOAc 
1:3). 
1
H NMR (500 MHz, CDCl3): δ (ppm) 2.49-2.63 (m, 2H, C5H4-CH2-CH2-CO), 2.70-2.83 (m, 4H, 
C5H4-CH2-CH2-CO, H7, H1), 2.87-2.98 (m, 2H, H6, H7), 3.10-3.15 (min) and 3.93-3.97 (maj) 
(rotamers, m, 1H, H3), 4.09-4.30 (m, 10H, H3, C5H4 and C5H5), 4.69 (min) and 4.75-4.84 (maj) 
(rotamers, m, 2H, H6, H11b), 3.90 (min) and 5.12 (maj) (rotamers, m, 1H, H1) 7.05-7.21 (m, 4H, C6H4). 
13
C{
1
H} NMR (126 MHz, CDCl3): δ (ppm) 25.9 (maj) and 26.3 (min) (rotamers, C5H4-CH2-CH2-CO), 
29.2 (maj) and 29.3 (min) (rotamers, C7), 35.4 (maj) and 35.7 (min) (rotamers, C5H4-CH2-CH2-CO), 
39.2 (min) and 39.6 (maj) (rotamers, C6), 45.6 (maj) and 46.7 (min) (rotamers, C1), 49.6 (maj) and 50.3 
(min) (rotamers, C3), 55.4 (maj) and 55.8 (min) (rotamers, C11b), 68.2 (C5H4), 68.4 (C5H4), 68.7 (min) 
and 68.9 (maj) (rotamers, C5H4), 69.1 (C5H4), 69.4 (maj) and 69.9 (min) (rotamers, C5H5), 88.1 (C5H4), 
125.9 (min) and 126.1 (maj) (rotamers, C6H4), 127.4 (min) and 127.5 (maj) (rotamers, C6H4), 128.1 
(maj) and 128.2 (min) (rotamers, C6H4), 129.8 (maj) and 130.1 (min) (rotamers, C6H4), 132.6 (min) and 
133.2 (maj) (rotamers, C6H4), 135.3 (maj) and 135.9 (min) (rotamers, C6H4), 164.6 (maj) and 165.9 
(min) (rotamers, C4), 171.3 (min) and 171.7 (maj) (rotamers, CH2-CH2-CO-N). ESI-MS (pos. detection 
mode): m/z (%): 442.1 (70) [M]
+
, 465.1 (100) [M+Na]
+
, 481.1 (80) [M+K]
+
. Anal. calcd. for 
C25H26FeN2O2: C 67.88, H 5.92, N 6.33. Found: C 68.09, H 5.78, N 6.19. 
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Compound 8A. 8A was synthesized following GP-1. 4-Ferrocenylbutyric acid (200 mg, 0.73 mmol), 
praziquanamine (148 mg, 0.73 mmol), HATU (418 mg, 1.1 mmol), DIPEA (188 mg, 1.46 mmol), 5 mL 
DMF and 7 h reaction time. Flash column chromatography (silica gel, hexane:EtOAc 1:2→1:3) gave 8A 
as an orange sticky solid (yield: 245 mg, 73%). Rf = 0.23 (silica gel, hexane:EtOAc 1:2).
 1
H NMR (500 
MHz, CDCl3): δ (ppm) 1.74-1.81 (m, 2H, C5H4-CH2-CH2-CH2), 2.19-2.37 (m, 4H, C5H4-CH2-CH2-CH2 
and C5H4-CH2-CH2-CH2), 2.67-2.91 (m, 4H, H1, H6, 2×H7), 3.91-4.02 (m, 10H, H3, C5H4 and C5H4), 
4.08 (min) and 4.22 (maj) (rotamers, d, 1H, H3), 4.71 (m, 2H, H6, H11b), 3.77 (min) and 5.05 (maj) 
(rotamers, m, 1H, H1), 7.07-7.24 (m, 4H, C6H4). 
13
C{
1
H} NMR (126 MHz, CDCl3): δ (ppm) 26.7 (maj) 
and 27.1 (min) (rotamers, C5H4-CH2-CH2-CH2), 29.3 (maj) and 29.4 (min) (rotamers, C5H4-CH2-CH2-
CH2), 29.7 (C7), 33.1 (min) and 33.3 (maj) (rotamers, C5H4-CH2-CH2-CH2), 39.2 (min) and 39.7 (maj) 
(rotamers, C6), 45.6 (maj) and 46.7 (min) (rotamers, C1), 49.6 (maj) and 50.2 (min) (rotamers, C3), 
55.5 (maj) and 55.6 (min) (rotamers, C11b), 67.9 (maj) and 68 (min) (rotamers, C5H4), 68.7 (C5H4), 
68.1 (C5H4), 68.2 (C5H4), 68.7 (maj) and 68.9 (min) (rotamers, C5H5), 88.7 (C5H4), 125.9 (min) and 
126.1 (maj) (rotamers, C6H4), 127.5 (min) and 127.6 (maj) (rotamers, C6H4), 128.1 (maj) and 128.2 
(min) (rotamers, C6H4), 129.9 (maj) and 130.2 (min) (rotamers, C6H4), 132.6 (min) and 133.3 (maj) 
(rotamers, C6H4), 135.3 (maj) and 136 (min) (rotamers, C6H4), 164.8 (maj) and 165.9 (min) (rotamers, 
C4), 171.6 (min) and 172 (maj) (rotamers, CH2-CH2-CO-N). ESI-MS (pos. detection mode): m/z (%): 
479.1 (100) [M+Na]
+
. Anal. calcd. for C26H28FeN2O2: C 68.43, H 6.18, N 6.14. Found: C 68.81, H 6.21, 
N 6.03. 
Compound 9A. 9A was synthesized following GP-1. 5-Ferrocenylpentanoic acid (200 mg, 0.69 
mmol), praziquanamine (141 mg, 0.69 mmol), HATU (398 mg, 1.05 mmol), DIPEA (180 mg, 1.4 
mmol), 5 mL DMF and 7 h reaction time. Flash column chromatography (silica gel, hexane:EtOAc 
1:1→0:1) gave 9A as an orange sticky solid (yield: 210 mg, 64%). Rf = 0.7 (silica gel, EtOAc).
 1
H NMR 
(500 MHz, CDCl3): δ (ppm) 1.48-1.52 (m, 2H, C5H4-CH2-CH2-CH2-CH2), 1.61-1.68 (m, 2H, C5H4-
CH2-CH2-CH2-CH2), 2.24-2.34 (m, 4H, C5H4-CH2-CH2-CH2-CH2 and C5H4-CH2-CH2-CH2-CH2), 2.70-
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2.93 (m, 4H, H1, H6, 2×H7), 3.97-4.07 (m, 10H, H3, C5H4 and C5H5), 4.18 (min) and 4.28 (maj) 
(rotamers, d, 1H, H3), 4.69-4.79 (m, 2H, H6, H11b), 3.91 (min) and 5.07 (maj) (rotamers, m, 1H, H1), 
7.07-7.24 (m, 4H, C6H4). 
13
C{
1
H} NMR (126 MHz, CDCl3): δ (ppm) 25.4 (C5H4-CH2-CH2-CH2-CH2), 
29.3 (maj) and 29.4 (min) (rotamers, C5H4-CH2-CH2-CH2-CH2), 30.0 (maj) and 30.1 (min) (rotamers, 
C7), 31.4 (maj) and 31.5 (min) (rotamers, C5H4-CH2-CH2-CH2-CH2), 33.7 (C5H4-CH2-CH2-CH2-CH2), 
39.2 (min) and 39.7 (maj) (rotamers, C6), 45.6 (maj) and 46.7 (min) (rotamers, C1), 49.5 (maj) and 50.1 
(min) (rotamers, C3), 55.5 (maj) and 55.9 (min) (rotamers, C11b), 67.8 (maj) and 67.9 (min) (rotamers, 
C5H4), 68.7 (maj) and 68.8 (min) (rotamers, C5H4), 69.1 (maj) and 69.2 (min) (rotamers, C5H5), 89.4 
(maj) and 89.5 (min) (rotamers, C5H4), 125.9 (min) and 126.1 (maj) (rotamers, C6H4), 127.5 (min) and 
127.6 (maj) (rotamers, C6H4), 128.1 (maj) and 128.3 (min) (rotamers, C6H4), 129.9 (maj) and 130.2 
(min) (rotamers, C6H4), 132.6 (min) and 133.3 (maj) (rotamers, C6H4), 135.3 (maj) and 136 (min) 
(rotamers, C6H4), 164.8 (maj) and 166.1 (min) (rotamers, C4), 171.7 (min) and 172.2 (maj) (rotamers, 
CH2-CH2-CO-N). ESI-MS (pos. detection mode): m/z (%): 493.1 (100) [M+Na]
+
. Anal. calcd. for 
C27H30FeN2O2: C 68.94, H 6.43, N 5.96. Found: C 68.81, H 6.40, N 5.91. 
Compound 10A. 10A was synthesized following GP-1. 4,4-diferrocenoylpentanoic acid (85 mg, 
0.16 mmol), praziquanamine (33 mg, 0.16 mmol), HATU (92 mg, 0.24 mmol), DIPEA (42 mg, 0.32 
mmol), 4 mL DMF and 7 h reaction time. Flash column chromatography (silica gel, hexane:EtOAc 
1:2→1:3) gave 10A as an orange solid (yield: 98 mg, 78%). Rf = 0.33 (silica gel, EtOAc:hexane 3:1). 
1
H 
NMR (500 MHz, CDCl3): δ (ppm) 1.59 (maj) and 1.63 (min) (rotamers, s, 3H, CH3), 2.23-2.42 (m, 4H, 
N-CO-CH2-CH2-C and N-CO-CH2-CH2-C), 2.65-2.89 (m, 4H, H1, H6, 2×H7), 3.10 (min) and 3.91 
(maj) (rotamers, d, 1H, H3), 3.97 (min) and 3.99 (maj) (rotamers, s, 10H, C5H5), 4.23-4.32 (m, 5H, H3 
and C5H4), 4.56 (m, 2H, C5H4), 4.66-4.75 (m, 4H, C5H4, H6 and H11b), 3.79 (min) and 5.03 (maj) 
(rotamers, m, 1H, H1), 7.06-7.23 (m, 4H, C6H4). 
13
C{
1
H} NMR (126 MHz, CDCl3): δ (ppm) 22.2 (maj) 
and 22.3 (min) (rotamers, CH3), 29.2 (H7), 29.3 (maj) and 29.4 (min) (rotamers, N-CO-CH2-CH2-C), 
33.3 (maj) and 33.8 (min) (rotamers, N-CO-CH2-CH2-C), 39.3 (min) and 39.6 (maj) (rotamers, C6), 
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45.7 (maj) and 46.8 (min) (rotamers, C1), 49.5 (maj) and 50.1 (min) (rotamers, C3), 55.5 (maj) and 56.1 
(min) (rotamers, C11b), 64.7 (maj) and 64.9 (min) (rotamers, C(CH3)), 70.7 (maj) and 70.8 (min) 
(rotamers, C5H5), 71.4, 71.5 (maj) and 71.6 (min) (rotamers, C5H4), 72.2 (C5H4), 72.3 (C5H4), 72.4 
(C5H4), 72.5 (maj) and 72.6 (min) (rotamers, C5H4), 79.1 (C5H4), 125.3 (maj) and 125.4 (min) 
(rotamers, C6H4), 127.5 (C6H4), 128.1 (maj) and 128.3 (min) (rotamers, C6H4), 129.8 (maj) and 129.9 
(min) (rotamers, C6H4), 132.6 (min) and 133.3 (maj) (rotamers, C6H4), 135.3 (maj) and 136 (min) 
(rotamers, C6H4), 164.6 (maj) and 165.8 (min) (rotamers, C4), 171.5 (min) and 171.9 (maj) (rotamers, 
N-CO-CH2-CH2-C), 200.5 (C-CO-C5H4). ESI-MS (pos. detection mode): m/z (%): 733.2 (100) 
[M+Na]
+
. Anal. calcd. for C39H38Fe2N2O4: C 65.94, H 5.39, N 3.94. Found: C 66.08, H 5.31, N 3.89. 
Compound 11A. 11A was synthesized following GP-1. 4,4-diferrocenoylbutanoic acid (150 mg, 0.29 
mmol), praziquanamine (59 mg, 0.29 mmol), HATU (167 mg, 0.44 mmol), DIPEA (76 mg, 0.59 mmol), 
4 mL DMF and 7 h reaction time. Flash column chromatography (silica gel, hexane:EtOAc 1:2→1:4) 
gave 11A as an orange solid (yield: 128 mg, 63%). Rf = 0.65 (silica gel, EtOAc).
 1
H NMR (500 MHz, 
CDCl3): δ (ppm) 2.33-2.52 (m, 4H, N-CO-CH2-CH2 and N-CO-CH2-CH2), 2.64-2.87 (m, 4H, H1, H6, 
2×H7), 3.18 (min) and 3.91 (maj) (rotamers, d, 1H, H3), 4.02-4.05 (m, 10H, C5H5), 4.24 (m, 1H, H3), 
4.45 (m, 4H, C5H4), 4.50 (m, 1H, CH(CO)2), 4.65-4.73 (m, 2H, H6, H11b), 4.84-4.87 (m, 4H, C5H4), 
3.80 (min) and 5.08 (maj) (rotamers, m, 1H, H1), 7.06-7.23 (m, 4H, C6H4). 
13
C{
1
H} NMR (126 MHz, 
CDCl3, mixture of tautomers): δ (ppm) 25.5 (maj) and 26.4 (min) (tautomers, N-CO-CH2-CH2), 29.2 
(maj) and 29.3 (min) (tautomers, C7), 31.3 (N-CO-CH2-CH2), 39.3 (min) and 39.6 (maj) (tautomers, 
C6), 45.7 (maj) and 46.8 (min) (tautomers, C1), 49.3 (maj) and 50.1 (min) (tautomers, C3), 55.4 (maj) 
and 56.1 (min) (tautomers, C11b), 61.3 (min) and 61.5 (maj) (tautomers, CH(CO)2), 70.5 (min) and 70.6 
(maj) (tautomers, C5H4), 70.7 (maj) and 70.8, 70.9 (min) (tautomers, C5H5), 73.2, 73.3, 73.4, 73.5 
(rotamers of tautomers, C5H4) 79.4 (maj) and 79.5 (min) (tautomers, C5H4), 126.1 (C6H4), 127.5 (maj) 
and 127.6 (min) (tautomers, C6H4), 128.1 (maj) and 128.2 (min) (tautomers, C6H4), 129.8 (maj) and 
130.6 (min) (tautomers, C6H4),  132.6 (min) and 133.3 (maj) (tautomers, C6H4), 135.3 (maj) and 135.8 
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(min) (tautomers, C6H4), 164.6 (maj) and 165.2 (min) (tautomers, C4), 170.9 (min) and 171.2 (maj) 
(tautomers, N-CO-CH2-CH2), 200.4 (maj) and 200.5 (min) (tautomers, CH(CO)2). ESI-MS (pos. 
detection mode): m/z (%): 719.2 (100) [M+Na]
+
, 735.2 (60) [M+K]
+
. Anal. calcd. for C38H36Fe2N2O4: C 
65.54, H 5.21, N 4.02. Found: C 65.71, H 5.30, N 3.94. 
Compound 12A. 12A was synthesized following GP-1. 1,1′-ferrocenedicarboxylic acid (200 mg, 
0.73 mmol), praziquanamine (442 mg, 2.19 mmol), HATU (832 mg, 2.19 mmol), DIPEA (282 mg, 2.19 
mmol), 10 mL DMF and 20 h reaction time. Flash column chromatography (silica gel, EtOAc:MeOH 
15:1) gave 12A as an orange solid (yield: 206 mg, 44%). Rf = 0.13 (silica gel, EtOAc).
 1
H NMR (500 
MHz, CDCl3): δ (ppm) 2.64-2.98 (m, 8H, H1, H6, 2×H7), 4.01 (m, 2H, H3), 4.34 (m, 4H, C5H4), 4.58 
(m, 2H, C5H4), 4.66 (m, 6H, C5H4, H3 and H6), 4.84 (m, 2H, H11b), 4.92 (m, 2H, H1), 7.06-7.12 (m, 
8H, C6H4). 
13
C{
1
H} NMR (126 MHz, CDCl3): δ (ppm) 29.3 (C7), 39.5 (C6), 47.3 (C1), 51.4(C3), 55.2 
(C11b), 71.6 (C5H4), 71.8 (C5H4), 72.2 (C5H4), 72.5 (C5H4), 72.6 (C5H4), 74.1 (C5H4), 74.2 (C5H4), 79.4 
(C5H4), 125.9 (C6H4), 127.5 (C6H4), 128.1 (C6H4), 129.9 (C6H4), 133.2 (C6H4), 135.3 (C6H4), 165.2 
(C4), 169.7 (N-CO-C5H4). ESI-MS (pos. detection mode): m/z (%): 665.3 (80) [M+Na]
+
, 1307.4 (70) 
[2M+Na]
+
. Anal. calcd. for C36H34FeN4O4: C 67.29, H 5.33, N 8.72. Found: C 67.08, H 5.18, N 8.54. 
 
Abbreviations. Fc – Ferrocenyl; PZQ – Praziquantel; Fc-PZQ – Ferrocenyl Praziquantel; HATU – 2-
(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; ESI-MS – 
Electrospray Ionisation Mass Spectrometry; DIPEA – Diisopropylethylamine; SAR – Structure Activity 
Relationship 
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